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A B S T R A C T
Objectives: In coronavirus disease 2019 (COVID-19), the adaptive immune response is of considerable
importance, and detailed cellular immune reactions in the hematological system of patients with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are yet to be clarified.
Methods: This study reports the morphological characterization of both bone marrow and spleen in 11
COVID-19 decedents with respect to findings in the peripheral blood and pulmonary SARS-CoV-2 burden.
Results: In the bone marrow, activation and left shift were found in at least 55% of patients, which was
mirrored by peripheral anaemia, granulocytic immaturity and multiple thromboembolic events. Signs of
sepsis-acquired immunodeficiency were found in the setting of an abscess-forming superinfection of
viral COVID-19 pneumonia. Furthermore, a severe B cell loss was observed in the bone marrow and/or
spleen in 64% of COVID-19 patients. This was reflected by lymphocytopenia in the peripheral blood. As
compared to B cell preservation, B cell loss was associated with a higher pulmonary SARS-CoV-2 burden
and only a marginal decrease of of T cell counts.
Conclusions: The results of this study suggest the presence of sepsis-related immunodeficiency in severe
COVID-19 pneumonia with superinfection. Furthermore, our findings indicate that lymphocytopenia in
COVID-19 is accompanied by B cell depletion in hematopoietic tissue, which might impede the durability
of the humoral immune response to SARS-CoV-2.
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
Over the past months, the pandemic spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed
more than 1.5 million lives (WHO, 2020). Current mortality rates
with severe coronavirus disease 2019 (COVID-19) are approxi-
mately 5%, which is relatively high as compared to death from
influenza (Faust and del Rio, 2020; Iuliano et al., 2018; WHO, 2020).
Although pulmonary factors such as diffuse alveolar damage and
pneumonia are major immediate causes of death in patients with
COVID-19, recent studies have proposed that endotheliitis and
thromboses contribute to the severity of pulmonary damage
(Ackermann et al., 2020; Bryce et al., 2020; Lax et al., 2020; Levi
et al., 2020; Varga et al., 2020). Nevertheless, the deduction of* Corresponding author at: Institute of Pathology, Charité–Universitätsmedizin
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).therapeutic algorithms from this knowledge is difficult. This
reflects the heterogeneity of the clinical outcomes of SARS-CoV-2























































J. Ihlow, E. Michaelis, S. Greuel et al. International Journal of Infectious Diseases 103 (2021) 628–635With regard to the pathophysiology of COVID-19, T cell-
ediated immunity seems to play a major role, which has been
inked to severe lymphocytopenia in the blood (Terpos et al., 2020;
heng et al., 2020). Recent findings also indicate a T cell-mediated
erminal centre atrophy in the lymph node and the spleen with
oss of germinal centre B cells in early COVID-19 (Kaneko et al.,
020). However, it is unclear whether bone marrow B cells are
ffected by the systemic invasion of SARS-CoV-2.
This study reports a post-mortem analysis of bone marrow and
plenic tissue in patients who died of COVID-19, which contributes
ubstantially to recent findings on the pathogenesis and adds
urther explanation regarding the lack of a durable immune
esponse in SARS-CoV-2 infection.
Materials and methods
tudy design
Post-mortem examinations were performed on a total of 15
atients. Eleven of these patients had PCR-confirmed SARS-CoV-2
nfection and were diagnosed with COVID-19. The remaining four
atients had died from cardiac conditions and were matched for age,
herebyserving asacontrol group. Onthe legalbasis ofx1 SRegG BEof
he autopsy act of Berlin and x25 of the German Infection Protection
ct, autopsies were either performed at Charité University Medical
entre Berlin or at Vivantes Hospitals Berlin. The study was
erformed in accordance with local ethics guidelines (ethics
ommittee approval EA2/066/20) and the Declaration of Helsinki.
ritten consent was obtained from all next of kin. Clinical data were
btained from the clinical records or death certificates.
utopsy procedure
A complete autopsy was performed in 11 patients with COVID-
9 and four control patients. Proper safety precautions were
ndertaken and the autopsies were performed in an enclosed
pace according to the safety guidelines (CDC, 2020). Pulmonary
amples, bone marrow from vertebral bodies, and splenic tissue
ere obtained for histopathology.
ample preparation and assessment
Bone marrow and spleen samples were fixed in formalin and
he bone marrow was then decalcified with a solution of 20%
thylenediaminetetraacetic acid (EDTA) for 8 h overnight. The
amples were then dehydrated and embedded in paraffin.
ections of paraffin-embedded bone marrow and spleen were
tained with haematoxylin–eosin (HE), periodic acid–Schiff stain
PAS), Giemsa, Gomori, and Prussian blue stains. Additionally,
mmunohistochemical staining was performed according to
tandard protocols provided by the LEICA Bond III, LEICA Bond
AX (Leica Biosystems, Buffalo, NY, USA) or the automated
entana BenchMark XT immunostainer (Ventana Medical Sys-
ems, Inc., Tucson, AZ, USA). Briefly, the tissue sections were
eparaffinized, rehydrated, and subjected to heat-induced epitope
etrieval and endogenous peroxidase blocking with H2O2. Subse-
uently, bone marrow slides were incubated for 30 min with the
ollowing primary antibodies and the indicated dilutions: CD235
1:400, Dako), myeloperoxidase (MPO, 1:3000, Dako), CD34 (1:50,
eica), CD117 (1:400, Dako), CD68 (1:200, Dako), CD61 (1:100,
eica), CD20 (1:750, Dako), CD3 (1:100, Dako), CD4 (1:20, Leica),
primary antibodies against Ki67 (1:100, Dako), CD20, CD3, CD4,
CD8, CD3, CD34, CD61, CD68, HLA-DR, and PD-L1. This was
followed by chromogen 3,30-diaminobenzidine tetrahydrochloride
(DAB) application for 8 min and counterstaining with haematox-
ylin (Ventana and Leica Bond) and bluing reagent (Ventana only)
for 12 min. All slides were examined with a Leica DMLB microscope
and a 40 ocular lens (field number 25) by at least two
haematopathologists. In the bone marrow, quantification of cell
types and apoptosis was performed by minimum counts of 10
high-power fields (HPF). The bone marrow evaluation was
conducted in analogy to morphological assessment of iliac
trephine biopsies (Tzankov et al., 2012). In splenic tissue, cells
were counted as percentage of specimen surface. Immunohisto-
chemical expression was classified by the percentage of stained
cells and staining intensity, which were graded as either strong,
moderate, weak, or absent.
Epstein–Barr virus in situ hybridization and PCR
For the bone marrow samples, Epstein–Barr virus (EBV)-encoded
ribonucleic acid (EBER RNA) in situ hybridization (ISH) was
performed using the automated Leica Bond III System in combina-
tion with anti-fluorescein antibodies and the BOND Polymer refine
detection system, consisting of HRP conjugated anti-rabbit anti-
bodies. 3,30-DAB was used as chromogen for visualization. Finally,
the slides were counterstained with haematoxylin.
As control for the EBER-ISH results, PCR was performed for the
determination of the viral EBV load. Deoxyribonucleic acid (DNA)
was extracted from biopsy specimens using the Maxwell RSC DNA
FFPE Kit (Promega). Subsequently, a conserved region of the
human EBV nuclear antigen 1 gene (EBNA1, BKRF1) was amplified
using ReddyMix PCR Master Mix (Thermo Fisher Scientific), a PCR
digoxigenin labelling mix (PCR DIG Labeling Mix, Roche), and a mix
of Epstein–Barr 30 and Epstein–Barr 40 primers.
SARS-CoV-2-specific PCR and subgenomic RNA assessment in
pulmonary tissue
Fifty milligrams of pulmonary tissue from each COVID patient was
homogenized. RNA was subsequently purified using the MagNA Pure
96 systemand the MagNA Pure 96DNA and Viral NA Large Volume Kit
(Roche) following the manufacturer’s instructions. The RNA extracts
were used for quantitative real-time PCR targeting the SARS-CoV-2 E-
gene. Viral RNA was quantified by in vitro RNA transcripts that had
been photometrically quantified prior to the study. Total DNA was
measured in all extracts using the Qubit dsDNA HS Assay Kit (Thermo
Fisher Scientific). Detection of subgenomic RNA (sgRNA) was
performed using oligonucleotides targeting the leader transcription-
al regulatory sequence and region within the sgRNA coding for the E-
gene, as described previously (Wölfel et al., 2020).
Statistical analysis
The data collection and statistical analysis were performed
using IBM SPSS Statistics version 23 (2017; IBM Corp., Armonk, NY,
USA) and GraphPad Prism 8 (2018; GraphPad Software, Inc.).
Comparisons between dichotomous groups were performed using
the Fisher’s exact test or Chi-square test. The time from onset to
death was analysed using the Kaplan–Meier method.D8 (1:100, Dako), CD138 (1:25, Dako), human leukocyte antigen
sotype DR (HLA-DR, 1:25, Leica), programmed cell death protein
nd ligand 1 (PD-1, 1:100, Epitomics; PD-L1, 1:200, Cell Signaling),
r caspase 3 (1:400, Zytomed). A horseradish peroxidase (HRP)-
onjugated secondary antibody (Leica) then was applied for 32
in. In the same manner, the spleen slides were stained with62Results
Causes of death in patients with COVID-19
Autopsies were performed on 11 patients with COVID-19-
initiated death and four control patients who died from cardiac9
J. Ihlow, E. Michaelis, S. Greuel et al. International Journal of Infectious Diseases 103 (2021) 628–635injuries who were matched for age. The median time from death to
autopsy was comparable in the two groups (p = 0.6), namely 3 days
in the COVID-19 patients (interquartile range (IQR) 1–5 days)
versus 2 days in the control cohort (IQR 1–3.5 days). The clinical
characteristics and causes of death with COVID-19 are shown in
Table 1 and Figure 1.
Histopathology of bone marrow and spleen of COVID-19 patients
To characterize the morphology of the bone marrow and spleen
of COVID-19 patients, a histopathological assessment in compari-
son to non-COVID-19 controls was performed (Figures 2 and 3).
Bone marrow from the vertebral bodies was available for all
patients. Splenic tissue was obtained from 10 COVID-19 deceased
patients and three control patients.
Seventy-three percent (n = 8) of COVID-19 patients presented
with hypercellularity and an increase in immature myelopoiesis
with precursors in the bone marrow. Moreover, megakaryopoiesis
was increased in COVID-19 patients, with a maximum value of 17
CD34- and CD117-positive cells were <5% in the bone marrow of
both COVID-19 and control patients.
Of alls COVID-19 patients, 55% (n = 6) showed mild fibrosis of
the bone marrow medullary space, which was not present in the
control cohort. As a correlate of monocytic activity, variability of
monocytic and macrophage cell shapes (round vs stellar-shaped)
was observed in 82% (n = 9) of COVID-19 patients. However, after
EDTA decalcification, the macrophage iron load was weak and
signs of hemophagocytosis were absent.
A substantial decrease of the white pulp was observed in the
spleen of all COVID-19 decedents but not in the control cohort.
CD34+ cells were <5% in all splenic samples. As compared to the
bone marrow, a moderate intracellular macrophage iron load was
found in 40% (n = 4) of COVID-19 spleens, which was paired with a
thickening of the splenic capsule and the trabecular arterioles and
therefore interpreted as a sign of chronic blood retention due to
right cardiac insufficiency.
COVID-19 is associated with severe B cell loss in bone marrow and
Table 1
Characteristics, treatment, and major autopsy findings in patients with severe COVID-19 pneumonia.
Entire COVID-19 cohort Immediate cause of death (autopsy)
Thrombosis or bleeding Right cardiac failure Sepsis
Characteristics n = 11 n = 5 n = 3 n = 3
Pulmonary SARS-CoV-2 RNA, log10 copies/ml, median (IQR) 2.46 (1.73–3.81) 2.24 (0.87–3.48) 2.46 (1.73–6.06) 2.74 (1.25–5.90)
Sex, n (%)
Female 5 (45) 1 (20) 1 (33) 3 (100)
Male 6 (55) 4 (80) 2 (67) 0 (0)
Age, years, median (IQR) 68 (62–79) 68 (62–74) 79 (71–90) 68 (45–79)
Time to death, days, median (95% CI) 19 (16–22) 19 (15–23) 26 (5–46) 19 (11–27)
Number of comorbidities, median (IQR) 5 (4–5) 5 (4–7) 4 (3–5) 5 (4–5)
Co-infectiona, n (%) 9 (82) 4 (80) 2 (67) 3 (100)
Chronic respiratory conditionsb, n (%) 7 (64) 4 (80) 2 (67) 1 (33)
Chronic cardiac conditionsc, n (%) 8 (73) 5 (100) 2 (67) 1 (33)
Chronic vascular conditionsd, n (%) 9 (82) 3 (60) 3 (100) 3 (100)
Chronic renal conditions, n (%) 2 (18) 1 (20) 0 (0) 1 (33)
Chronic gastrointestinal conditionse, n (%) 5 (45) 2 (40) 1 (33) 2 (67)
Chronic endocrine conditionsf, n (%) 3 (27) 2 (40) 0 (0) 1 (33)
Autoimmune diseasesg, n (%) 1 (9) 1 (20) 0 (0) 0 (0)
Chronic haematological conditions, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
History of solid neoplasiah, n (%) 2 (18) 2 (40) 0 (0) 0 (0)
Anticoagulation, n (%) 8 (73) 4 (80) 2 (67) 2 (67)
Antibiotic treatment, n (%) 11 (100) 5 (100) 3 (100) 3 (100)
ICU (invasive ventilation, ECMO, HD), n (%) 9 (82) 4 (80) 2 (67) 3 (100)
ES frequency, median (IQR) 2 (1–6) 2 (1.5–4.5) 6 (0–13) 2 (0–11)
TS frequency, median (IQR) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0)
FFP frequency, median (IQR) 0 (0–14) 0 (0–16) 0 (0–0) 5 (0–27)
Microthrombi, autopsy proof, n (%) 9 (82) 4 (80) 2 (67) 3 (100)
ARDS, autopsy proof of DAD, n (%) 9 (82) 4 (80) 3 (100) 2 (67)
Pulmonary abscesses, autopsy proof, n (%) 3 (27) 0 (0) 0 (0) 3 (100)
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; log, logarithm; RNA, ribonucleic acid; n, number of patients; IQR, interquartile range; CI, confidence interval;
ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; HD, haemodialysis; ES, erythrocyte substitution concentrate; TS, thrombocyte substitution
concentrate; FFP, fresh frozen plasma; ARDS, acute respiratory distress syndrome; DAD, diffuse alveolar damage; HIV, human immunodeficiency virus; HSV-1, herpes simplex
virus 1.
a Co-infection included bacterial (Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecium), viral (HIV, HSV-1), and fungal (Candida
species) pathogens.
b Respiratory conditions comprised chronic obstructive pulmonary disease, asthma, and obstructive sleep apnoea syndrome.
c Cardiac conditions comprised cardiac insufficiency, chronic ischemic heart disease, hypertensive heart disease, and persistent arrhythmias.
d Vascular conditions comprised arterial hypertension, atherosclerosis, and peripheral arterial occlusive disease.
e Gastrointestinal conditions comprised liver cirrhosis and peptic ulcer.
f Endocrinological conditions comprised diabetes mellitus type II, hypothyreosis, and dyslipoproteinemia.
g Autoimmune disease was rheumatoid arthritis.
h Solid neoplasia comprised history of squamous cell lung cancer or basal cell carcinoma.megakaryocytes/HPF as compared to 9 megakaryocytes/HPF in
control patients. Bone marrow megakaryocytes of COVID-19
patients showed signs of immaturity with cell diameters of <20
mm and hypolobulated nuclei in 55% (n = 6). Peripheral or visceral
microthrombi were found in 82% (n = 9) of COVID-19 cases but
were absent in the control cohort.630spleen
After the basic assessment, the lymphatic components of the
bone marrow and spleen were evaluated. Strikingly, a severe loss of
B cells with a subsequent CD20+ B cell depletion in either bone



















J. Ihlow, E. Michaelis, S. Greuel et al. International Journal of Infectious Diseases 103 (2021) 628–635igure 1. Ante-mortem laboratory findings from peripheral blood samples that were drawn within the week prior to death from 11 patients with COVID-19 as compared to
hose of the four control patients.
ote: Red dots represent findings in COVID-19 patients with B cell depletion in either spleen or bone marrow (n = 7), green dots represent findings in COVID-19 patients with B
ell preservation (n = 4), black hashes represent findings in the control cohort (n = 4). Centre values represent the median of the entire cohort (n = 15) and error bars indicate
he standard deviation of the pooled values. The upper and lower normal limits for each value are charted as grey zones.
bbreviations and conversion factors: RBC, red blood cell count; MCV, median corpuscular volume; MCH, median corpuscular haemoglobin; PLT, platelets; INR, international
ormalized ratio (prothrombin time ratio between patient sample and standard sample); aPTT, activated partial thromboplastin time; WBC, white blood cell count; CRP, C-
eactive protein (multiply by 9.5238 to convert to nmol/l); IL-6, interleukin 6.
igure 2. Post-mortem histopathological findings in the bone marrow and in the spleen tissue of 11 COVID-19 deceased patients as compared to four control patients.
ote: Red dots represent findings in COVID-19 patients with B cell depletion in either spleen or bone marrow (n = 7), green dots represent findings in COVID-19 patients with B
ell preservation (n = 4), black hashes represent findings in the control cohort (n = 4). Centre values represent the median of the entire cohort (n = 15) and error bars indicate
he standard deviation of the pooled values.
bbreviations: G:E, granulocytopoiesis to erythrocytopoiesis ratio.n the group of patients with B cell loss, CD20+ B cell counts were
1% in the bone marrow and 1–5% in the spleen (Figure 3). Of these
atients, three had combined B cell loss in both bone marrow and
pleen, whereas two had either isolated B cell loss in the bone
arrow or in the spleen. Moreover, plasma cell depletion was63observed in four out of five patients who had CD20+ B cell loss in
the bone marrow. These changes were absent in the control cohort.
Although complete CD20+ B cell loss was not observed in the
remaining four COVID-19 decedents, CD20+ B cell counts were still
lower than in the control cohort. More precisely, median CD20+ B1
J. Ihlow, E. Michaelis, S. Greuel et al. International Journal of Infectious Diseases 103 (2021) 628–635cell counts were 2% in the bone marrow and 5% in the spleen within
the COVID-19 cohort, as compared to 7% and 15% in the control
cohort (Figure 2). In COVID-19 patients with B cell preservation,
the remaining B cells had a tendency towards mixed nodular
aggregation (n = 4).
Quite contrary to the severe loss of B cells, T cell counts were
marginally decreased in the bone marrow of COVID-19 patients
(median 10%) as compared to the control cohort (median 12.5%). In
the bone marrow, the maximum T cell/B cell ratio was 10:0 in
the COVID-19 patients had an HIV co-infection and received
antiretroviral therapy.
Next, an analysis was conducted to determine whether severe B
cell loss in COVID-19 patients was linked to the viral SARS-CoV2
burden or determined by a specific clinical risk profile. Interest-
ingly, a tendency towards a higher SARS-CoV-2 RNA load was
observed in pulmonary tissue of patients with complete B cell loss,
particularly when the bone marrow was affected. Although median
viral copy numbers were approximately equal in both groups
Figure 3. CD20+ B cell loss in a COVID-19 deceased patient (age 79 years) as compared to a control patient (age 78 years). (A) Histopathology of cell-rich areas in the bone
marrow show immaturity of myelopoiesis (left row), severe loss of CD20+ B cells (middle row), and a stabilized CD3+ T cell count (right row) in the COVID-19 patient as
compared to the control patient. (B) Histopathology of the spleen shows atrophy of peri-arteriolar white pulp (left row), caused by loss of CD20+ B cells (middle row); the peri-
arteriolar CD3+ T cell distribution is regular (right row).
Abbreviations: HPF, high power field; H&E, haematoxylin and eosin; BM, bone marrow; SPL, spleen.COVID-19 patients as compared to 3:1 in the control samples.
Comparable effects of only slight Tcell reduction in the spleen were
observed (Figures 2K and 3). T cell subpopulations were skewed
towards a CD8+ phenotype with CD4/CD8 ratios of on average 1:2
(range 1:1–1:4) in COVID-19 patients as compared to 1:1 (range
2:1–1:1) in the bone marrow of the control cohort. Of note, one of632(Table 2), maximum viral copy numbers of nearly 800,000 and
1,150,000/10,000 cells in patients with total B cell loss as compared
to 6500/10,000 cells in patients with B cell preservation were
observed.
In order to identify a possible B cell EBV reactivation during





















J. Ihlow, E. Michaelis, S. Greuel et al. International Journal of Infectious Diseases 103 (2021) 628–635one marrow specimens, combined with additional PCR clarifica-
ion. Both techniques revealed an absence of EBV. Clinical
haracteristics were equally distributed between COVID-19
atients with and without B cell loss (p-values >0.5 in all pairwise
omparisons). Moreover, intervals from onset of symptoms to
eath were heterogeneous in both groups (Table 2).
igns of sepsis-acquired immunodeficiency after severe bacterial
uperinfection of viral COVID-19 pneumonia
Autopsy revealed sepsis due to abscess-forming pneumonia in
7% (n = 3) of COVID-19 patients (Figure 4). Of these patients, one
elonged to the group with B cell loss and two were in the group
ith B cell preservation. Clinically, these patients were in septic
shock prior to death and either swabs or pulmonary lavage showed
bacterial superinfection of the underlying COVID-19 pneumonia
with Staphylococcus aureus, Staphylococcus epidermidis, or Pseudo-
monas aeruginosa. To determine whether sepsis-related immuno-
suppression had been present prior to death in these three
patients, an additional immunological characterization of the bone
marrow microenvironment was performed by grading immuno-
histochemical expression of B and T cell markers, HLA-DR, caspase
3, and PD-L1 in relation to pulmonary SARS-CoV-2 levels and
intervals from onset of symptoms to death (Figure 4). Immuno-
histochemistry revealed signs of sepsis-acquired immunodeficien-
cy in the bone marrow that were reflected morphologically by an
increase in bone marrow cellularity and immature myeloid cell
types with multiple myeloid precursors. Furthermore, an increase
able 2
haracteristics of 11 patients with severe COVID-19 pneumonia and B cell loss or B cell preservation in the bone marrow or spleen.
Characteristics of the COVID-19 cohort (n = 11) Severe B cell loss (n = 7) B cell preservation (n = 4)
Pulmonary SARS-CoV-2 RNA level, log10 copies/ml, median (IQR) 2.46 (1.73–5.90) 2.69 (1.49–3.64)
Age, years, median (IQR) 71 (68–79) 65 (61–76)
Time to death, days, median (95% CI) 19 (6–32) 19 (16–22)
Number of comorbidities, median (IQR) 4 (3–5) 5 (5–5)
Viral co-infection, n (%) 1 (14) 1 (25)
Bacterial co-infection, n (%) 3 (43) 3 (75)
Fungal co-infection, n (%) 1 (14) 1 (25)
HIV, n (%) 1 (14) 0 (0)
Autoimmune disease, n (%) 0 (0) 1 (25)
History of solid malignancy, n (%) 2 (30) 0 (0)
ICU (invasive ventilation, ECMO, HD), n (%) 6 (86) 3 (75)
Sepsis, n (%) 5 (71) 3 (75)
Pulmonary abscesses, autopsy proof, n (%) 2 (30) 1 (25)
ARDS with autopsy proof of DAD, n (%) 5 (71) 4 (100)
ARS-CoV-2, severe acute respiratory syndrome coronavirus 2; log, logarithm; RNA, ribonucleic acid; n, number of patients; IQR, interquartile range; CI, confidence interval;
U, intensive care unit; ECMO, extracorporeal membrane oxygenation; HD, haemodialysis; ARDS, acute respiratory distress syndrome.igure 4. Signs of sepsis-acquired immunodeficiency and relative development of bone marrow morphology according to the interval from onset of symptoms to death in
hree COVID-19 deceased patients with abscess-forming superinfection of viral pneumonia. (A) Expression levels of immunological markers, (B) cell types and presence of
orphological characteristics, (C) morphological results of bone marrow evaluation in each patient.
bbreviations: HLA-DR, human leukocyte antigen DR isotype; APC, antigen-presenting cells; PD-L1, programmed death ligand 1; SARS-CoV-2, severe acute respiratory
yndrome coronavirus 2; MPS, monocyte–macrophage system; MC, myeloid cells; HPF, high-power field.
633
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(characterized by caspase 3) and an increase in neutrophilic PD-L1
expression were observed in the two patients with fulminant
sepsis and early death. These changes were combined with an early
loss of B cells and an increase in pulmonary SARS-CoV-2 levels.
Furthermore, we observed a continuous decrease in monocytic
activation with transition from numerous round-shaped CD68-
positive monocytes in the bone marrow of these two patients with
early death as compared to fewer stellar-shaped CD68-positive
macrophages in the patient who died later. The latter was
accompanied by a decrease in HLA-DR expression on monocytes,
macrophages, and dendritic cells, especially in the patient with
prolonged sepsis.
Discussion
This study gives a detailed insight into the morphology of bone
marrow and splenic tissue reactions in COVID-19 decedents. This
appears to be the first study to examine the specific role of bone
marrow B cells in the context of COVID-19-associated lymphocy-
topenia. Furthermore, information is provided on the sepsis-
related pathophysiology in patients with COVID-19 pneumonia
with pulmonary bacterial co-infection.
Confirmatory to recent COVID-19 autopsy reports, thrombo-
embolic events, bleeding, right cardiac failure, and sepsis with
abscess-forming pneumonia and consecutive severe pulmonary
damage were observed as immediate causes of death (Bryce et al.,
2020; Elezkurtaj et al., 2020; Lax et al., 2020; Wichmann et al.,
2020). The median age of the study cohort was 68 years and thus
comparable to that of COVID-19 decedents reported in other
studies (Bryce et al., 2020; Zhou et al., 2020). Since thromboem-
bolic events, bleeding, or sepsis were present in the vast majority
(73%) of patients, COVID-19-associated changes in hematopoietic
tissue were of particular interest here.
As a correlate of hyperinflammation, recent studies have reported
excessive macrophage stimulation and signs of consecutive hemo-
phagocytosis in the bone marrow of a subset of COVID-19 patients
(Bryce et al., 2020; Merad and Martin, 2020). Consistent with an
acute-phase reaction, hypercellularityand predominantly immature
granulopoiesis with multiple myeloid precursors were observed in
the bone marrow, mirrored by a release of immature granulocytes
and anemia in the peripheral blood (Figures 1 and 2). Furthermore,
regenerating megakaryopoiesis was found, which probably resulted
from thromboembolic events that were present in 82% of the study
cohort, and this could be explained by hyperinflammation-
associated endothelial dysfunction (Bryce et al., 2020; Varga et al.,
2020). In turn, the latter might have contributed as a mediator for the
release of immature granulocytes or myeloid suppressor cells to the
periphery via microscopic rupture of the endothelial barrier in the
bone marrow (Venet et al., 2020).
Hemophagocytosis was not present in the study cohort. Instead,
signs of incipient sepsis-acquired immunodeficiency were found in
the bone marrow of patients with severe bacterial superinfection
of COVID-19 pneumonia. This was reflected by an early increase in
myeloid PD-L1 expression, lymphocytic apoptosis, and macro-
phage anergy with loss of antigen-presenting capacity (Hotchkiss
and Nicholson, 2006; Huang et al., 2014; Landelle et al., 2010).
Usually, sepsis-acquired immunodeficiency is accompanied by
cytokine-related T cell exhaustion, the release of myeloid
suppressor cells, and epigenetically determined monocyte switch
However, due to the limited number of cases, these findings need
to be interpreted with caution.
Apart from immunodeficiency, severe lymphocytopenia in the
peripheral blood has been reported as an adverse risk factor for the
clinical outcome of COVID-19 patients (Chen et al., 2020; Tan et al.,
2020; Terpos et al., 2020; Zheng et al., 2020) and there is increasing
evidence that this is caused by a follicular atrophy in lymphoid
organs (Bryce et al., 2020; Buja et al., 2020; Kaneko et al., 2020; Lax
et al., 2020). A recent study by Kaneko et al. indicated a crucial
impact of tumour necrosis factor alpha (TNF-α) that leads to early
blockage of B cell lymphoma 6 protein (BCL6)-positive T helper
cells with a consecutive loss of BCL6-positive germinal centre B
cells in early stages of COVID-19, and therefore to a dysregulation
of the humoral immune response (Kaneko et al., 2020). In the
present study, severe lymphocytopenia was consistently observed
in the peripheral blood, in the spleen, and even in the bone marrow
of more than half of the COVID-19 cohort, which was combined
with a release of immature granulocytes, elevated C-reactive
protein, and increased interleukin 6 levels in the peripheral blood
(Figure 1I–L). This suggested an ongoing acute phase reaction but
an inadequate specific immune response in these patients.
Unfortunately, peripheral B/T cell counts were not available for
the study cohort of COVID-19 decedents. However, in the spleen
and in the bone marrow, the severe loss of lymphocytes was
predominantly caused by a depletion of B cells rather than by a loss
of T cells (Figure 2E, F, J, L). Therefore, the findings strongly
emphasize a separate involvement of B cells in the pathogenesis of
COVID-19, since viral sepsis usually results in a significant decrease
of both CD4+ T cells and CD20+ B cells (Hotchkiss et al., 2001). In
the subgroup of patients with severe B cell loss, pulmonary SARS-
CoV-2 levels were exceedingly high, and a distinct clinical risk
profile was absent as compared to patients with B cell preservation
(Table 2). Hence, SARS-CoV-2-associated effects were the most
probable link towards the observed B cell loss, although the
relatively small sample size precluded the detection of statistically
significance differences between the two groups. Furthermore, it
should be mentioned that B cell counts in the bone marrow are
generally low, with median values ranging from 2% to 5% in the
literature (Fauci, 1975) and 7% in the control cohort of the present
study. Nevertheless, the co-occurrence of both loss of B cells and
loss of plasma cells allows for the assumption of an excessive
activation of B cell-specific pathways such as the B cell trans-
forming growth factor beta (TGF-β) pathway (Chua et al., 2020;
Islam et al., 1991). The latter seems reasonable, since a recent study
by Biasi et al. reports a significant loss of naïve and mature B cells
accompanied by an expansion of immunoglobulin M+ plasma-
blasts in the peripheral blood of patients with COVID-19
pneumonia (De Biasi et al., 2020). In analogy to therapy-induced
B cell depletion under treatment with rituximab, systemic
immunoglobulin therapy might be helpful in the subset of
COVID-19 patients with severe B cell loss.
In conclusion, the study findings indicate that infection with
SARS-CoV-2 is related to mechanisms of sepsis-acquired immu-
nodeficiency, as well as B cell and plasma cell depletion in
hematopoietic tissues. Since B cells and plasma cells are major key
players of acquired immunity, the study findings add further
explanation to the limited durability of the humoral immune
response to SARS-CoV-2 (Kaneko et al., 2020; Long et al., 2020)
and thus contribute to the pathophysiological understanding of
COVID-19.to endotoxin tolerance after bacterial stress (Biswas and Lopez-
Collazo, 2009; Boomer et al., 2011; Cheng et al., 2016; Lorente-
Sorolla et al., 2019). Thus, methylation-related predisposition for
immune memory adaption may influence the highly variable
outcome and affect later immunity in patients with severe
bacterial co-infection of COVID-19 pneumonia to a varying extent.634Funding
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